Solu-Medrol® (methylprednisolone sodium succinate) – New contraindication and warning

- The FDA approved an update to the *Contraindications* section of the Solu-Medrol (methylprednisolone sodium succinate) drug label regarding the 40 mg formulation including lactose monohydrate produced from cow's milk.
    - The Solu-Medrol 40 mg formulation is therefore contraindicated in patients with a known or suspected hypersensitivity to cow's milk or its components or other dairy products because it may contain trace amounts of milk ingredients.
- Solu-Medrol is approved to treat a variety of indications including allergic conditions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system disorders, ophthalmic diseases, renal diseases, respiratory diseases, rheumatic disorders, and miscellaneous diseases such as trichinosis and meningitis.
    - Consult Solu-Medrol's drug label for detailed indication information.
- The *Warnings and Precautions* section was also updated to include the following information when treating acute allergic conditions:
    - In patients receiving the Solu-Medrol 40 mg formulation during the treatment for acute allergic conditions and where these symptoms worsen or any new allergic symptoms occur, consideration should be given to the potential for hypersensitivity reactions to cow's milk ingredients.
    - If appropriate, administration of Solu-Medrol should be stopped, and the patient's condition should be treated accordingly.
    - Alternative treatments, including the use of corticosteroid formulations that do not contain ingredients produced from cow's milk, should be considered for acute allergy management, where appropriate.